CONTENT ANALYSIS OF THE RANGE OF ANTINEOPLASTIC DRUGS REGISTERED IN THE REPUBLIC OF UZBEKISTAN

Admin bo'lib kirish (www.admin.slib.uz)

Tizim sinov (TEST) rejimida ishlamoqda! Murojat uchun @slib_support

Eski talqinga o'tish link

5 август 2025

Asosiy til:Ingliz

CONTENT ANALYSIS OF THE RANGE OF ANTINEOPLASTIC DRUGS REGISTERED IN THE REPUBLIC OF UZBEKISTAN

Fan yo'nalishi:

689237b303251.pdf

PDF

Eurasian Journal of Medical and Natural Sciences

Maqola chop etish see more

MAQOLA ANNOTATSIYASI

This article presents a comprehensive content analysis of antineoplastic drugs registered in the Republic of Uzbekistan between 2022 and 2024. Based on the The State Register of Medicines and medical devices and medical equipment approved for use in medical practice of the Republic of Uzbekistan (the State Register), the study focuses on pharmacotherapeutic groups L01, L02, L03, and L04 according to the ATC classification. The number of registered trade names, the proportion of imports, and domestic production were evaluated. Special attention was given to alkylating agents, antimetabolites, taxanes, antitumor antibiotics, and targeted therapies. The study identifies key international nonproprietary names with stable or declining registration dynamics and highlights gaps in the current pharmaceutical supply. Findings emphasize the country's reliance on foreign suppliers, especially for high-tech drugs, and suggest directions for localization and import substitution to strengthen pharmaceutical self-sufficiency

MUALIFLAR

Teglar

# Uzbekistan# content analysis# import# localization# registration# oncology# Antineoplastic drugs# pharmaceutical market# ATC classification

Maqolani baholang

0

0 ta

Maqola idintifikatorlari

ROI:

https://eroi.uz/11.0201/A0825-0009

DOI:

Mavjud emas

Foydalanilgan adabiyotlar

1.Gopienko, I. A., & Zyryanov, S. K. (2024). Marketing analysis of the Russian pharmaceutical oxaliplatin market. Qualitative Clinical Practice, (1), 72-77.2.Nemchenko, A. S., & Fursa, L. I. (2016). Marketing research of the market of antitumor drugs for the treatment of lung cancer. Social pharmacy in the protection of health, (2), 59-67.3.Суюнов, Н. Д., Ражабова, Н. Х. (2020). Ўзбекистон Республикасида рўйхатдан ўтган саратонга қарши дори воситаларининг таҳлили. Фармацевтический журнал, 1(4), 3-10.4.Н. Х. Ражабова, & Н. Д. Суюнов (2024). АНАЛИЗ И ПРОГНОЗ ПОТРЕБНОСТИ В ПРОТИВООПУХОЛЕВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВАХ В РЕСПУБЛИКЕ УЗБЕКИСТАН. Вестник фармации, (1 (103)),36-48. doi: 10.52540/2074-9457.2024.1.365.Tillyashaykhov, M. N., Ibragimov, S. N., & Dzhanklich, S. M. (2020). Analysis of the main statistical indicators of the oncological service of the Republic of Uzbekistan. Clinical and Experimental Oncology, (2), 5-10.6.Mikhel, D. (2017). Personalized Medicines: Ideology, Marketing and Social Consequences of the Distribution (Personalized Medicines: Ideology, Marketing and Social Consequences of the Distribution). Philosophical and Anthropological Foundation of Personalized Medicine (Interdisciplinary Analysis). Workbooks on Bioethics. Edited by PD Tishchenko. Moscow, 7-25. 7.M.N. Tillyashaykhov, N.Kh. Rajabova, N.D. Suyunov, & S.M. Djanklich (2024). Эпидемиология и прогноз заболеваемости онкологическими болезнями, раком легкого и бронхов. Вестник Витебского государственного медицинского университета, 23 (3), 47-55. doi: 10.22263/2312-4156.2024.3.47